Canaccord raised the firm’s price target on Edwards Lifesciences (EW) to $63 from $60 and keeps a Hold rating on the shares. The firm said Q3 results relatively in line with expectations and said given the capacity constraints the company continues to highlight, even if early TAVR shows compelling data, they don’t believe there could be meaningful volume increases in the near term.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EW:
- Edwards Lifesciences price target raised to $78 from $72 at JPMorgan
- Edwards Lifesciences price target lowered to $68 from $73 at Baird
- Closing Bell Movers: Deckers up 12% after earnings beat
- Edwards Lifesciences reports Q3 adjusted EPS 67c, consensus 64c
- Edwards Lifesciences backs FY24 revenue growth view 8%-10%, consensus $1.44B
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
